Evidence map›Paper›PMID 35889510›Full record

ArticleMolecules (Basel, Switzerland)2022

Gene Expression and Protein Abundance of Nuclear Receptors in Human Intestine and Liver: A New Application for Mass Spectrometry-Based Targeted Proteomics.

Christoph Wenzel, Lisa Gödtke, Anne Reichstein, Markus Keiser, Diana Busch, Marek Drozdzik, Stefan Oswald

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Assessment of cytochrome P450 induction in canine intestinal organoid models.Xenobiotica; the fate of foreign compounds in biological systems · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Christoph WenzelDepartment of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17475 Greifswald, Germany.ORCID 0000-0002-4361-7575
Lisa GödtkeDepartment of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17475 Greifswald, Germany.
Anne ReichsteinDepartment of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17475 Greifswald, Germany.
Markus KeiserDepartment of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17475 Greifswald, Germany.ORCID 0000-0003-4842-6273
Diana BuschDepartment of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17475 Greifswald, Germany.
Marek DrozdzikDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0002-6191-7168
Stefan OswaldInstitute of Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.
Universitätsmedizin Greifswald · DEPomeranian Medical University · PLUniversity of Rostock · DE

Funding

German Federal Ministry for Education and Research (InnoProfile-Transfer) 03IPT612A
6 · The paper itself

Abstract

backgroundUnwanted drug-drug interactions (DDIs), as caused by the upregulation of clinically relevant drug metabolizing enzymes and transporter proteins in intestine and liver, have the potential to threaten the therapeutic efficacy and safety of drugs. The molecular mechanism of this undesired but frequently occurring scenario of polypharmacy is based on the activation of nuclear receptors such as the pregnane X receptor (PXR) or the constitutive androstane receptor (CAR) by perpetrator agents such as rifampin, phenytoin or St. John's wort. However, the expression pattern of nuclear receptors in human intestine and liver remains uncertain, which makes it difficult to predict the extent of potential DDIs. Thus, it was the aim of this study to characterize the gene expression and protein abundance of clinically relevant nuclear receptors, i.e., the aryl hydrocarbon receptor (AhR), CAR, farnesoid X receptor (FXR), glucocorticoid receptor (GR), hepatocyte nuclear factor 4 alpha (HNF4α), PXR and small heterodimer partner (SHP), in the aforementioned organs.

methodsGene expression analysis was performed by quantitative real-time PCR of jejunal, ileal, colonic and liver samples from eight human subjects. In parallel, a targeted proteomic method was developed and validated in order to determine the respective protein amounts of nuclear receptors in human intestinal and liver samples. The LC-MS/MS method was validated according to the current bioanalytical guidelines and met the criteria regarding linearity (0.1-50 nmol/L), within-day and between-day accuracy and precision, as well as the stability criteria.

resultsThe developed method was successfully validated and applied to determine the abundance of nuclear receptors in human intestinal and liver samples. Gene expression and protein abundance data demonstrated marked differences in human intestine and liver. On the protein level, only AhR and HNF4α could be detected in gut and liver, which corresponds to their highest gene expression. In transfected cell lines, PXR and CAR could be quantified.

conclusionsThe substantially different expression pattern of nuclear receptors in human intestinal and liver tissue may explain the different extent of unwanted DDIs in the dependence on the administration route of drugs.

Indexed as

ProteomicsReceptors, SteroidChromatography, LiquidConstitutive Androstane ReceptorGene ExpressionHepatocytesHumansIntestinesLiverPharmaceutical PreparationsReceptors, Cytoplasmic and NuclearTandem Mass SpectrometryConstitutive Androstane ReceptorPharmaceutical PreparationsReceptors, Cytoplasmic and NuclearReceptors, Steroiddrug-drug interactionenzymeshumanintestinelivernuclear receptorstransporters

Identifiers

PMID35889510
PMCPMC9318449
OpenAlexW4286503825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.